Compound Radar

Personalis, Inc. (PSNL) Stock Analysis

Price $16.60
Market cap $1.82B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

41
41/100 Avoid
  • Financial Health 25
  • Profitability 40
  • Business Quality 60
  • Balance Sheet 35
  • Cash Flow 60

Why this rating?

Health 41/100 — Avoid

Strongest Business Quality 60/100
Softest Financial Health 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Personalis, Inc. (PSNL) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Personalis, Inc. 41/100 (Avoid) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -18.13
  • EV/Revenue 23.66

Profitability

  • Revenue Growth 30.0%
  • Gross Margin 12.7%
  • Operating Margin -150.2%
  • Net Margin -153.8%
  • ROE -50.3%

Financial strength

  • Cash $212.66M
  • Debt $38.00M
  • Net Cash $174.66M
  • Free Cash Flow $-79.45M
  • Current Ratio 5.28

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks Personalis, Inc. (PSNL).

View Methodology & FAQ →